Company Filing History:
Years Active: 2020
Title: Ruth Bielsa Guivernau: Innovator in Pharmaceutical Composition
Introduction: Ruth Bielsa Guivernau is a talented inventor based in Palleja, Spain. She has made significant contributions to the field of pharmaceuticals, particularly with her innovative approach to peptide therapeutics. With a single patent to her name, Ruth stands out for her dedication to improving drug formulations.
Latest Patents: Ruth Bielsa Guivernau holds a patent for a pharmaceutical composition aimed at achieving sustained release of lanreotide. This composition is designed to provide a sustained release compatible with therapeutic treatments lasting at least two months. The innovative composition includes lanreotide as the active agent, alongside a hydrosoluble co-solvent and water, maintaining a pH between 4.0 and 7.5. This advancement demonstrates her commitment to enhancing patient care through prolonged efficacy of medications.
Career Highlights: Currently, Ruth works at Ipsen Pharma S.A.S., where she leverages her expertise in pharmaceutics. Her role at such a well-regarded company highlights her capabilities in developing pioneering drug formulations that address complex medical needs. Ruth's work contributes not only to her institution but also to the broader field of pharmaceutical sciences.
Collaborations: Throughout her career, Ruth has collaborated with esteemed colleagues, including Roland Cherif-Cheikh and Julie Fournes. These partnerships underline the importance of teamwork in the research and development process, showcasing how diverse expertise can lead to groundbreaking innovations in pharmaceuticals.
Conclusion: Ruth Bielsa Guivernau represents the future of pharmaceutical innovation, combining her scientific knowledge with practical applications. Her patent for a sustained release of lanreotide may greatly impact therapeutic practices, ultimately benefiting patients worldwide. As she continues her work at Ipsen Pharma S.A.S., the pharmaceutical community eagerly anticipates her future contributions.